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Abstract
Background: Exercise has been shown to maintain or increase bone mineral density (BMD) in non-CF populations. Objectives:
The purpose of our study was to elucidate the relationship between exercise, body composition and dietary intake with BMD in
an adult CF population with heterogeneous disease severity. Design: We measured spinal (L1-4) and femoral (femoral neck)
BMD by dual energy X-ray absorptiometry (DEXA) in 68 CF adults (24 female, 44 male) with a mean age 30.8(1.7) and
27.4(1.3) (range 18–55) years. We used the average BMD Z score for spine and femoral neck for analyses. Differences in
disease severity, exercise capacity, physical activity level, dietary intake, body composition, body mass index (BMI), glucocorticoid
use were correlated with BMD scores. Exercise capacity was defined as the maximal amount of oxygen consumed by muscles
during maximal exercise (VO ). Vertebral and non-vertebral fracture rate were also recorded. Results: Fifty-seven patients were2max
identified with low BMD (Z score-y1). Multiple linear regression identified exercise capacity and BMI as significant predictors
of BMD. Later diagnosis of CF was also associated with low adult BMD. Conclusions: Low BMD is common in adult CF
patients. Exercise capacity and BMI are predictors of low BMD.
 2003 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
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1. Introduction
Cystic fibrosis (CF) is an autosomal recessive multi-
system disease with pulmonary and gastrointestinal man-
ifestations. With therapeutic advances, CF patients are
living beyond their adolescent years well into adulthood.
Long-term complications from the disease are now more
frequently seen in association with their increased lon-
gevity. These disorders include low bone mineral density
and increased fracture risk. In normal adults, peak bone
mass is achieved around age 30 years. Genetic factors
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probably account for 70% of an individual’s peak bone
mass with the remainder due to diet, exercise, disease
and environmental factors w1x. Specific parameters con-
tributing to peak bone mass are dietary calcium, other
dietary factors (vitamin D, caloric intake), weight,
activity and sex hormone exposure as indicated by
reproductive and menstrual history in women w2x.
As with the respiratory manifestations of CF, the
pancreatic and GI tract manifestations of the disease are
related to the failure of epithelial ion transport. As a
consequence, enzymes required for digestion of protein
and fat will be lost, resulting in malabsorption of protein,
fat, fat-soluble vitamins and calcium. Pancreatic enzyme
supplementation improves, but does not always normal-
ize absorption. Malnutrition may result in poor somatic
growth as well as skeletal growth, delayed puberty and
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skeletal maturation, low body mass, deficiency in fat-
soluble vitamins (including vitamin D) and poor calcium
absorption. Plasma 25-hydroxyvitamin D (25-OH vita-
min D) levels have been commonly reported to be low
in CF patients w3–8x despite oral supplementation
w6,8,9x. Adequacy of dietary intake to estimated requi-
rements and expenditures in relation to BMD has not
been addressed.
In most series, pulmonary disease severity is the best
predictor of BMD. This factor, however, only moderately
predicts BMD w5,6,8,10x. Exercise, an important predic-
tor of BMD in non-CF populations, has in the CF
population usually been evaluated by recall question-
naires of activity and has not accurately predicted BMD.
Other associations with low BMD in CF patients include
homozygosity for the DF508 mutation w4x, delayed
puberty w5,7,8,10x, hypogonadism w7,8x, diabetes, corti-
costeroid use w11,12x and chronic pulmonary infection.
As CF patients’ life expectancy continues to improve,
it is important to anticipate adverse long-term skeletal
effects and to appropriately intervene in patients at risk.
Exercise has been shown as an important determinant
of BMD in the non-CF population. The benefits of
exercise in CF are multifactorial and exercise is also
prescribed as a chest physiotherapy modality. This study
determines the relationship of exercise capacity and
nutritional status and dietary intake on BMD in an adult
CF population with heterogeneous severity of pulmonary
disease.
2. Methods
2.1. Subjects
This study was prospective and cross-sectional.
Patients were recruited from the St. Paul’s Hospital
Adult Cystic Fibrosis clinic, which serves most of the
adult CF patient population for the province. The diag-
nosis of CF was confirmed by clinical signs and two
elevated sweat chloride tests or CFTR genotyping. All
consenting CF patients attending the St. Paul’s Hospital
Adult CF clinic over a 2-year period were recruited. A
total of 67 patients (over 18 years of age) exhibited
mild to severe airway obstruction were recruited from a
potential of 140 patients attending the clinic. Transplant-
ed patients (lung, heart-lung, liver) were excluded.
Patient evaluations were made during periods of clinical
stability without hospitalization or home therapy with
intravenous antibiotics for pulmonary infection within 1
month of entry.
St. Paul’s Hospital and the University of British
Columbia ethics committee approved the study and
study participants consented to participating by signing
the study consent following an explanation of the study.
2.2. Clinical measurements
Measurements were taken during stable clinical status
(non-pulmonary exacerbation). A pulmonary exacerba-
tion was defined as a pulmonary infection that required
intravenous antibiotic intervention. Subjects performed
spirometry including forced expiratory volume in 1 s
(FEV ) and forced vital capacity (FVC) according to1
ATS criteria with instruments adhering to accepted
standards w13x. Values were expressed as the percentage
of normal values based on age, gender and height. The
best-recorded post-bronchodilator measurements were
used for the study. Schwachman–Kulczycki (S–K)
scores were calculated. Chest and lateral spine radio-
graphs were obtained from patients’ charts, as was
information on activity patterns, pulmonary and nutri-
tional status for S–K scoring as described by Schwach-
man and Kulczycki w14x. Chest radiographs were scored
utilizing the Brasfield clinical scoring system w15x.
Corticosteroid use was documented both during puberty
and at the time of measurement of BMD. Patients were
classified as corticosteroids users if usage was for 2
months per year or more. The number of pulmonary
infections requiring intravenous antibiotic therapy (i.e.
number of pulmonary infections over 12 months and
mean days on IV therapy per infectious episode) was
gathered via chart review.
In this study we defined exercise capacity as the
direct measurement of maximal oxygen consumption
(VO ) and specifically as the maximum amount of2max
oxygen consumed by the muscles during a progressive
incremental exercise test to maximal effort. VO test2max
was performed on a Monark stationary bicycle and
followed a continuous progressive incremental regimen
w16x. Patients were categorically grouped as exercisers
or sedentary based on exercise habits (defined as exer-
cisers if they performed a minimum three 20-min exer-
cise sessions per week.
Patients were asked to complete a questionnaire on
fracture history. The fracture history questionnaire used
by the Canadian Multicenter Osteoporosis Study
(CaMOS) was used. Information was collected on frac-
ture history, cause of fractures and trauma level to
indicate how the fracture happened (due to severe or
minimal trauma or due to other diseases) w17x. Thoracic
and lumbar spine radiographs were examined for evi-
dence of thoracic vertebral compression, evaluated semi-
quantitatively by the Genant method w18x. Anterior, mid
and posterior vertebral heights were measured from the
anteroposterior chest radiographs and the least value
expressed as a percentage of maximum vertebral height.
A 20% decrease in vertebral height was indicative of
vertebral compression and kyphosis was measured with
a surveyor’s flexicurve w19x.
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2.3. Laboratory measurements
Subjects completed a 3-day dietary recall diary where
they were asked to record all foods, beverages and
supplements taken for 2 weekdays and one weekend
day or non-working day, analyzed using Nutritionist IV
(Microsoft Windows 1995, First DATABank division of
The Heart Corporation, 1111 Bayhill drive, San Bruno,
California 94066, USA). Supplements were incorporated
into specific nutrient totals. The 3-day recall used in
this study is the one regularly used by the CF dietician
for nutritional assessment.
2.4. Bone mineral density and body composition
measurements
We obtained lumbar spine (L1-4), proximal femur
(femoral neck and total hip including trochanter, Ward’s
triangle), and total body BMD using the DEXA scanner
(Norland Medical Systems Inc., 1998) and the Norland
normative data set 392. Bone mass was expressed as
bone mineral density (gycm ) and bone mineral content2
(grams). In order to account for differences in age of
our patients, BMD data are expressed as Z scores (S.D.
below age, racial and sex matched control subjects,
Norland). Average Z score of L1-L4 and femoral neck
were used for all analyses. Normal bone density was
defined as a BMD above 1 standard deviation (S.D.)
below the mean for young healthy adults; osteopenia is
1–2.5 S.D.’s below mean for young adults; osteoporosis
is G2.5 S.D.’s below mean for young adults according
to World Health Organization criteria. We also obtained
total lean muscle mass, total fat mass using DEXA.
Studies have shown that use of DEXA for measurement
of fat and lean muscle mass is better than skinfold or
bioelectrical impedance, but as with these other meas-
urement techniques regional differences in fat distribu-
tion in males and females will affect readings w20,21x.
2.5. Statistical analysis
Data analysis was performed using SPSS version 7.0
(SPSS Inc., Chicago, IL, USA). Data are reported as
mean "S.E. of the mean (S.E.M.). Relationships
between covariates are described using Pearson product
moment or Spearman coefficient for non-parametric
data. We utilized for multiple regression analysis a
composite score for L1-L4 lumbar spine BMD and
femoral neck BMD as the dependent variable. Age and
gender were included in the regression analyses as
covariates. Stepwise regression was used to examine the
contribution of exercise (VO and exercise activity2max
status), BMI, current nutritional status (caloric intake,
calcium and vitamin D intake) and pulmonary disease
severity (i.e. %FEV ) to low BMD. The number of1
subjects available for analysis ranged from 46 to 67.
3. Results
3.1. Patient characteristics
Reduced BMD was a common finding in our CF
cohort (67 patients who participated in the study, 17 of
the 67 patients tested had BMD z-scores ofy2 or less).
Table 1 summarizes the demographic characteristics of
the study population, exercise capacity, clinical measures
of disease severity by BMD. To ensure that our study
sample was representative of the clinic population, we
compared participants and clinic non-participant CF
patients on a number of clinical parameters (for age
(28.6(1.0) vs. 29.8(1.3) years, Ps0.89; BMI (21.1(0.4)
vs. 21.4(0.40) kgym , Ps0.46), and gender (MyF ratio2
44y24 vs. 34y30, Ps0.27) and showed no significant
differences. For %predFEV there was a statistically1
significant difference between the study group and clinic
non-participants (57.6(3.0) vs. 63.9(3.7)%, Ps0.001),
however, the difference is not considered clinically
significant. Variables reported in this paper were checked
for normality and are normally distributed.
3.2. Exercise and nutritional status
Our stepwise regression model including BMI,
VO , age and gender accounted for 35% of the2max
variance for BMD (BMDsy4.68q0.14=BMIq
0.04=VO y0.01=AGE-0.14=SEX; Ps0.0001,2max
Ns65). Measures of pulmonary disease severity were
not significant predictors of BMD when VO was2max
entered into the analysis. Exercise capacity is lower in
the low BMD groups (Table 1). VO and BMD were2max
moderately correlated (rs0.42, Ps0.001), and this
value was higher than correlations of BMD with com-
mon measures of disease severity (i.e. (%predFEV : rs1
0.35, Ps0.004; S–K clinical score: rs0.40, Ps0.001
and Brasfield score: rs0.38, Ps0.001). VO was2max
moderately associated with these measures of disease
severity in CF (i.e. %predFEV : rs0.45, Ps0.0001;1
S–K scores: rs0.47, Ps0.0001; and Brasfield score:
rs0.43, Ps0.0001).
Another variable we investigated was age of CF
diagnosis. Although this variable was neither an impor-
tant predictor of BMD status, nor did we show signifi-
cant associations with measures of disease severity,
VO or nutritional status, we found that the patients2max
in our group who were classified as osteoporotic were
significantly older and were diagnosed with CF later in
life. Although gender was not a significant predictor of
BMD, there were more male patients in both the
osteopenic and osteoporotic groups. In our study we did
not show a significant association between BMD and
homozygosity for DF508 mutation (rsy0.13, Ps0.34,
Ns52).
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Table 1
Characteristics of study subjects by BMD classifications
Variable G : Normal1 G : Osteopenic2 G : Osteoporotic3 P-value Significant
(Z score-y1.0) (Z score: y1.0 to 2.5) (Z scoreG2.5) post-hoc
differences
Sample size 11 48 9
Gender 6y5 32y16 6y3
(maleyfemale)
Age at time of 27.0 (1.6) 30.6 (1.1) 37.5 (4.0) 0.01 Normal-Osteoporotic
testing (years)
Age at time of 1.4 (0.9) 2.8 (0.8) 11.5 (4.6) 0.003 Normal-Osteoporotic
CF diagnosis (years) Osteopenic-Osteoporotic
%PredFEV (%)1 69.5 (7.4) 59.0 (3.5) 35.4 (4.8) 0.006 Normal)Osteoporotic
Osteopenic)Osteoporotic
S–K scores 74.1 (5.3) 68.6 (2.1) 48.9 (6.7) 0.001 Normal)Osteoporotic
Osteopenic)Osteoporotic
Brasfield scores 18.0 (1.3) 15.2 (0.6) 10.9 (1.6) 0.001 Normal)Osteoporotic
Osteopenic)Osteoporotic
Frequency of 1.1 (0.4) 0.85 (0.2) 1.8 (0.6) 0.14
pulmonary infections
over 12 months
Pulmonary 17.8 (1.2) 16.1 (1.4) 17.3 (1.6) 0.82
exacerbations
(IV daysytxt)
Table 2
Exercise capacity and nutritional characteristics of study subjects by BMD classifications
Variable G1: Normal G2: Osteopenic G3: Osteoporotic P-value Significant
(Z score-y1.0) (Z score: y1.0 to 2.5) (Z score)2.5) post-hoc
differences
VO2max 32.4 (3.0) 30.5 (1.2) 22.6 (3.3) 0.03 Normal)osteoporotic
(ml kg min ). y1. y1 Osteopenic)osteoporotic
% of predicted 78.5 (5.8) 73.7 (2.7) 57.3 (7.8) 0.04
VO (%)2max
Pancreatic 2y9 6y41 1y8 0.87q
sufficiency
(sufficientyinsufficient)
BMI 23.4 (1.4) 21.1 (0.4) 19.2 (0.7) 0.01 Normal)osteoporotic
Fat mass (g) 21307.7 (4055.9)* 13946.4 (883.9) 12399.7 (2164.4) 0.01 Normal)osteopenic
Normal)osteoporotic
Lean mass (g) 44826.1 (2619.6)* 44155.6 (1213.0) 40367.2 (2387.4) 0.41
Total sample available 11 48 9
for analysis
Data available for 9, 35 and 7 of the subjects in the normal, osteopenic and osteoporotic groups.*
3.3. Dietary status
Eighty seven percent of study patients were pancreatic
insufficient (2, 6 and 1 in the normal, osteopenic and
osteoporotic groups, respectively, were pancreatic suffi-
cient) and were on enzyme supplementation. Table 2
shows BMI, body composition measures and calculated
caloric intake by BMD status.
3.4. Kyphosis and cumulative vertebral fractures
There were no significant associations between BMD,
exercise or nutritional status parameters and vertebral
fractures or kyphosis (results not shown). Kyphosis,
vertebral fractures of T8-T12, and %predFEV were1
predictors of low BMD, but this association could only
explain 11% (Ps0.005) and 8% (Ps0.01), respective-
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ly, of the variability for low BMD by the variables
kyphosis and vertebral fracture (results not shown).
3.5. Prevalence of non-vertebral fractures
We did not observe an increased fracture risk in our
osteoporotic group. We did observe a greater incidence
of refracture in the osteopenic group. Fracture and
refracture incidences were more common in those sub-
jects who lead a more active lifestyle (regular partici-
pation in sports). Two out of the three normals and 11
out of the 12 osteopenic subjects who experienced
fractures classified themselves as active (moderately
active to heavy labor). These individuals also engaged
in regular sports, which likely increased their risk of
fracture (results not shown).
3.6. Steroid use
We documented steroid use at puberty and current
use via chart review. Patients classified as taking corti-
costeroids were taking inhaled preparations (Beclov-
ent, Beclofort, Flovent, Pulmacort) for the study
duration. There were no significant differences in uses
of inhaled corticosteroids during adulthood by BMD
grouping (Normal 5 out of 10, Osteopenic 17 out of 48,
Osteoporosis 5 out of 9; x s1.6, Ps0.4). Only three2
patients were on short-term oral corticosteroids at puber-
ty (1 and 2 characterized as normal and osteopenic at
adulthood, respectively).
4. Discussion
Exercise capacity and nutritional status are predictive
of BMD in CF patients. Exercise capacity and BMI
were the best predictors and explained a moderate
portion of the variance for hip and spine BMD. The
prevalence of low BMD in our current sample was high,
only 15% of our sample had normal BMD for their age
and gender. Thirteen and 72% of our sample were
classified as osteoporotic (i.e. Z scoreG2.5) and osteo-
penic (i.e. Z score: y1.0 to 2.5), respectively. Twenty-
five percent of our sample had BMD Z scores of y2.0
or less, which according to Cummings and colleagues
suggests a threefold increased risk of fracture compared
to individuals of the same age and gender with normal
BMD w22x. Haworth et al. and Bhudhikanok and asso-
ciates showed higher prevalence of BMD Z scores of
y2 or less (43% and 53%, respectively) in their cohorts
of younger CF patients but similar pulmonary disease
severity w4,8x. This value was higher in the study by
Donovan and associates on CF patients with end-stage
pulmonary disease (73.3%) w6x.
VO was an important predictor of BMD status,2max
better than measures of pulmonary disease severity.
VO is a measure of the maximal amount of oxygen2max
consumed by the muscles and is a direct measurement
of exercise capacity. The reason why VO may be a2max
better predictor of BMD is that this parameter is also
affected by lean muscle mass or BMI as well as
pulmonary function. A positive relationship has been
shown between BMD and exercise in healthy normal
children w23x and young adults w24x, with exercise
playing a role in further increasing BMD before the
onset of puberty w25x. Gains in BMD achieved through
physical activity have also been shown to be short-
lived; with gains lost with cessation of the activity, and
this has been shown both in athletic populations w26,27x
and in intervention studies aiming to augment BMD
w27,28x. To our knowledge this is the only CF study
investigating BMD, which has directly measured exer-
cise status; previous CF studies have used recall diary
questionnaires to quantitate activity level, which has not
been shown as a significant predictor of BMD w3,5,8x,
but in some studies they showed higher fitness to be
associated with higher BMD in univariate analyses
w3,4,11x. Measurement of exercise capacity from patient
recall is indirect and can be inaccurate and less sensitive
than direct measurement of exercise capacity.
Level of pulmonary disease will also affect the inten-
sity of exercise and the mode of exercise in this cohort,
therefore, a direct measurement of exercise capacity
allows for a more objective measurement of exercise
status. With increasing pulmonary disease severity, a CF
patient may adopt a lower exercise training intensity to
minimize oxygen desaturation and the sensation of
breathlessness. This switch in exercise mode and inten-
sity inferring lower impact may also translate to a lower
benefit for bone health. Activity recall questionnaires
may not be as sensitive to identifying this change in
mode, intensity and duration of exercise sessions. Even
so, non-aerobic forms of exercise such as strength
training which have been shown to be beneficial in
BMD augmentation or maintenance would not necessar-
ily be associated with high VO . Therefore, some2max
form of activity questionnaire in concert with a VO2max
test would be optimum. Prescription of regular weight
bearing exercise and possibly strength training to main-
tain BMD would seem to be indicated and of benefit in
this population and should be further studied.
Previous studies have identified measures of disease
severity such as %predFEV and S–K clinical scores or1
other related clinical scores to be moderately associated
with BMD w3–5,8,29–31x. The lack of significant cor-
relations between disease severity and BMD in other
studies w6,7,32x is likely related to the homogeneity of
their study subjects (i.e. characterized predominantly by
severe pulmonary disease or low BMD). BMD studies
on children have generally shown declining trends in
BMD with increasing age and pulmonary disease sever-
ity w31x, even within the first 18 years w31x. It is clearly
difficult to distinguish between progressive decline in
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pulmonary and overall clinical status in CF patients and
aging as they are integrally-related. In our analyses
disease severity measures (i.e. %predFEV , S–K and1
Brasfield) were not included in the final model, but
univariate analyses did show significantly lower values
in patients with low BMD. This is not surprising as we
showed exercise capacity to be moderately associated
with these measures. A higher correlation was shown
between VO and the disease severity parameter, S–2max
K scores, which includes a measure of activity and BMI
in its construct. There are a number of possible mecha-
nisms which have been set forth to explain how severity
of pulmonary disease could affect BMD. One is a
reduced capacity for exercise with increased severity of
pulmonary disease. Loss of appetite may also occur
with increasing symptoms of disease progression.
Changes in disease management with increased use of
corticosteroids with the progressive increase in pulmo-
nary disease may adversely affect BMD w9x. Another is
chronic inflammation and infection and resulting
increased production of inflammatory cytokines may
also interfere with bone growth and bone mineral accre-
tion w33,34x as well as contribute to weight loss and
muscle wasting w33,35x.
Lifestyle or other events, which may have occurred
during childhood preventing CF children from achieving
peak bone mass during the critical pubertal years is
another possibility for low BMD in adulthood. In our
study cohort, CF patients classified as osteoporotic were
diagnosed as having CF later in life. Pancreatic insuffi-
ciency was common in our study group. Both these
factors have implications for attainment of peak bone
mass. Later diagnosis could mean that pancreatic abnor-
malities may have been overlooked and underlying
nutritional deficiencies neglected during the interim,
consequently affecting (slowing or permanently stunt-
ing) growth during puberty and jeopardizing attainment
of peak bone mass. Losses in BMD may have started
in childhood in this group or alternatively BMD losses
may be greater compared to patients diagnosed within
the first few years of life in relative terms because their
attained peak bone mass is lower. Even in those diag-
nosed in childhood, severe pulmonary disease is usually
linked with poor physical growth and poor nutritional
status and while significant declines in BMD are not
always shown at this stage w36x; these clinical parame-
ters invariably contribute to the low BMD in adulthood
w5,11,37,38x.
Current macro- and micronutrient dietary intake was
not predictive of BMD, as has been shown previously
w3,7x. Low 25-OHD levels indicative of vitamin D
deficiency have been shown in the literature even with
adequate caloric intake and vitamin D supplementation
w3–8,11x. This latter phenomenon may also be related
to inadequate exposure to sunlight w39x. Another possi-
bility is that pancreatic disease was not adequately
managed, which has been previously documented in this
population w40x, but may also be related to increased
catabolism in patients who have more severe disease.
These values only give us a snapshot of current dietary
intake and nutritional status and do not provide us,
however, with a picture of the patient’s nutritional intake
during the pivotal skeletal growth years. However, our
results suggest that we should monitor dietary and
supplement intake in those CF patients with apparent
normal BMD as a preventative measure to ensure
optimal BMI and continuing normal BMD in their
future.
Increased bone turnover has been shown in prepub-
ertal, pubertal and young CF adults (even though these
patients’ caloric intake was 150% of recommended and
were on vitamin D and calcium supplementation) w29x
and in CF patients with low BMD w4x. Homozygosity
for the DF508 mutation has been shown to be associated
with higher levels of some bone turnover markers (i.e.
BS-APase and urinary deoxypyridinoline crosslinks)
compared to heterozygotes for the DF508 mutation. As
more severe disease is usually associated with a DF508
genotype both from a pulmonary and pancreatic (i.e.
pancreatic insufficiency) perspective this is not surpris-
ing. In this case, dietary inadequacy, chronic higher
levels of inflammatory cytokines as well as inactivity
would be associated phenotypes. Heer and associates
showed increases in bone formation and decreases in
bone resorption markers in anorexia nervosa patients
following an 11-week dietary plan to increase BMI from
14.2 to 17.1 kgym w41x. Adequate dietary intake to
maintain BMI within the normal range may have added
importance in maintaining BMD.
Only a few studies have investigated the association
between kyphosis, fracture frequency and low BMD but
results as in our study have been inconclusive, likely
due to small sample size and the cross-sectional nature
of these studies. Fracture studies suggest an association
between low bone mass and incident fractures w6,42x,
especially in CF patients on long-term prednisone w7,8x.
Non-vertebral fractures were common in our study
cohort and while it would seem that fractures were more
common in those with BMD Z score -y2.5, this may
simply be due to our small group of patients with BMD
Z score Gy2.5. This paradox may be explained, how-
ever, as study patients with BMD Z score-y2.5 had
higher VO and less severe pulmonary disease, which2max
would suggest a more active lifestyle and thus increased
opportunity for injury and fracture. Patients with BMD
Z scoreGy2.5, however, were characterized with lower
VO and more severe pulmonary disease and conse-2max
quently were more likely to be sedentary and thus less
likely to be in a fracture-causing setting. This view is
supported by others w3,7,8,11,29x. Contrary to previous
findings w3,5,32x, we showed no associations between
vertebral fractures or degree of kyphosis and low spinal
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BMD. CF patients in the latter two studies were char-
acterized as having more severe pulmonary disease
w5,32x, which has been associated with increased prev-
alence of kyphosis and more pronounced vertebral
wedging w43x.
Long-term corticosteroid use is likely to affect BMD
in CF and has been documented in other populations
such as asthma and chronic obstructive lung disease
(COPD) w44,45x including CF w3,8,11,12x. Others
including our own study have not found an association
between corticosteroid use and low BMD w7,29,46x. Use
was minimal in our cohort, however, and was limited to
short-term use of inhaled forms.
In conclusion, VO and BMI are important predic-2max
tors of BMD in adult CF patients. Osteoporosis is also
a known common complication of organ transplantation
and it is, therefore, important to assist CF patients to
maintain normal BMD values so as to reduce pre and
post-transplant fracture risk. As maintenance of BMD is
a life-long process, it is important to make certain that
CF patients receive adequate caloric and nutrient intake
during the critical growth years in order to achieve peak
bone mass as well as adopt a life-long exercise regime.
Adequate pancreatic enzyme supplementation in pancre-
atic insufficient patients is also imperative to ensure
maximal absorption of vitamin D and other nutrients
and, therefore, the prevention of malnutrition. Early
diagnosis of CF will also guarantee that malabsorption
problems are aggressively addressed during childhood.
Regular aerobic weight bearing exercise would have
multifactorial benefits in this population. Longitudinal
studies investigating BMD, diet, exercise, growth and
attainment of peak bone mass, chronic corticosteroid
use, the role of inflammatory cytokines in bone loss
will definitively determine the impact of childhood
practices and the chronic inflammatory nature of CF on
adult BMD.
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